HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E4449 AG 825 AG-825 (Tyrphostin AG-825) is a potent and selective inhibitor of ErbB2 with IC50 values of 0.15 µM. It also inhibits PDGFR autophosphorylation with IC50 value of 40 µM. It exhibits anti-cancer activity and significantly induces apoptosis in cancer cells. Jan 22 2024
E1810 dCeMM1 dCeMM1 is a degrader of RBM39. dCeMM1 functions by altering the activity of the CRL4DCAF15 ligase, and also decreases RBM39 expression levels in wild-type KBM7 cells. Jan 22 2024
E1752 JNJ-42226314 JNJ-42226314 is a potent, selective, and reversible noncovalent inhibitor of monoacylglycerol lipase (MAGL). It enhances the expression of endocannabinoid 2-arachidonoylglycerol (2-AG) and exhibits antinociceptive efficacy in models of neuropathic and inflammatory pain. Jan 22 2024
E4453 Cathepsin G Inhibitor I Cathepsin G Inhibitor I exhibits reversible, competitive cathepsin G inhibition with IC50 and Ki values of 53 nM and 63 nM respectively. It can be used in antigen-processing studies and for modulation of T cell response in situ and in vivo. Jan 22 2024
E1711 FHT-1015 FHT-1015 is a potent, small-molecule, allosteric inhibitor of SMARCA4/SMARCA2 ATPase with IC50 values ≤10 nM. FHT-1205 decreases PD1+TIM3+ cells and cytokine expression in vivo. Jan 21 2024
E1634 CH6953755 CH6953755 is a potent, orally active, and selective inhibitor of YES1 kinase with an IC50 of 1.8 nM. CH6953755 demonstrates antitumor activity against YES1 gene-amplified cancers. Jan 21 2024
S6392 SHIN1(RZ-2994) SHIN1 (RZ-2994) is an inhibitor of SHMT1/2 (human serine hydroxymethyltransferase 1 and 2) with IC50 values of 5 and 13 nM, respectively, in in vitro assay. SHIN1 hinders cell growth by gradually reducing purine levels. Jan 21 2024
E4580 Sovleplenib Sovleplenib(HMPL-523) is a highly potent and selective SYK inhibitor with IC50 of 0.025 μM, that exhibits anti-tumor activities in vitro and in vivo. Sovleplenib exhibits synergistic activities in combination with BTK, PI3Kδ, and Bcl2 family inhibitors in killing human-diffused large B cell lymphoma (DLBCL). Jan 17 2024
E1769 Merbarone Merbarone(NSC 336628) is a catalytic inhibitor of topoisomerase II with IC50 of 120 μM, with anti-proliferative activity against human cancer cells. Merbarone acts primarily by blocking topoisomerase II-mediated DNA cleavage. Jan 17 2024
E1604 Vevorisertib trihydrochloride Vevorisertib trihydrochloride(ARQ 751 trihydrochloride) is a selective, allosteric inhibitor of pan-AKT and AKT1-E17K mutant with Kd values of 1.2 nM and 8.6 nM, respectively. It also has IC50 values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively and can be used for the research of cancer. Jan 16 2024
A3176 Human IgG2sa isotype control Human IgG2sa isotype control is suitable for use as a non-targeting isotype control in various in vitro and in vivo studies, is the isotype control of human IgG2sa antibody. Jan 15 2024
E1667 LY2880070 LY2880070 is an orally active inhibitor of CHK1. LY2880070 can be used as an anticancer agent and shows promise in preclinical models of pancreatic ductal adenocarcinoma (PDAC) when used in combination with DNA-damaging agents. Jan 10 2024
E1812 N6F11 N6F11 is an inducer of ferroptosis. N6F11 is bound to the RING domain of the E3 ubiquitin ligase tripartite motif containing 25 (TRIM25) in cancer cells to trigger TRIM25-mediated K48-linked ubiquitination of glutathione peroxidase 4 (GPX4), resulting in proteasomal degradation. Jan 10 2024
E1739 MST-312 MST-312(Telomerase Inhibitor IX) is an inhibitor of telomerase. MST-312 is a chemically modified derivative of green tea epigallocatechin gallate (EGCG). MST-312 exhibits high chemical stability, lowers the effective dose in the induction of telomere shortening, and lowers drug resistance. MST-312 can be used for the research of cancer. MST-312 can also be used as a promising strategy in the treatment of multiple myeloma (MM). Jan 10 2024
E1658 PRT543 PRT543 is a potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5) with broad antitumor activity in vitro and in vivo. It also inhibits the methyltransferase activity of the PRMT5/MEP50 complex with an IC50 of 10.8 nM. Jan 09 2024
E1744 UNC5293 UNC5293 is a potent, highly selective, orally available inhibitor of MER receptor tyrosine kinase (MERTK) with IC50 of 0.9 nM and Ki 0.19 nM. Jan 09 2024
E1742 Reversan Reversan (CBLC4H10) is a selective and nontoxic inhibitor of multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (P-gp), with the potential to treat neuroblastoma and other MRP1-overexpressing drug-refractory tumors. Jan 09 2024
E1723 NSC16168 NSC16168 is a specific inhibitor of ERCC1-XPF, and exhibits an IC50 value of 0.42 μM in a high throughput screen (HTS) assay, respectively. NSC16168 inhibits DNA repair and potentiates cisplatin efficacy in cancer. Jan 09 2024
E1746 Protokylol hydrochloride Protokylol hydrochloride(Caytine hydrochloride, JB-251 hydrochloride) is a salt form of protokylol and is an agonist of β-adrenergic receptor. Protokylol hydrochloride is also used as a bronchodilator. Jan 07 2024
E1727 Pimicotinib Pimicotinib (ABSK021) is an orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF1R). It enhances antitumor T-cell immune responses and inhibits the proliferation of tumor cells having potential immunomodulatory and antineoplastic activities. Jan 07 2024